Correction to article about GE's health-care division
01 Diciembre 2019 - 1:17PM
Noticias Dow Jones
General Electric Co.'s biopharma business accounted for 60% of
the almost $5 billion in revenue from the company's life-sciences
segment last year. "GE Pitches Investors on Its Health-Care Unit, a
Steady Source of Cash," at 8 a.m. ET, incorrectly stated in the
ninth paragraph that the biopharma business accounted for 75% of
the segment's $4 billion in revenue. (Dec. 1, 2019)
(END) Dow Jones Newswires
December 01, 2019 14:02 ET (19:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GE Aerospace (NYSE:GE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
GE Aerospace (NYSE:GE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
